Skip to content

Press Release Details

Seres' news, events and other information can be found throughout the pages below.

Seres Therapeutics to Host Microbiome R&D Event and Webcast on May 24, 2018

May 17, 2018 at 7:00 AM EDT

CAMBRIDGE, Mass.--(BUSINESS WIRE)--May 17, 2018-- Seres Therapeutics, Inc. (NASDAQ:MCRB) today announced that the Company will host a Microbiome R&D Day on Thursday, May 24, 2018, from 8:00 a.m.–10:30 a.m. ET in New York, NY.

The event will feature presentations from Seres management and leading academic subject matter experts on the microbiome as a new therapeutic target, with a focus on the Seres pipeline and the opportunity for microbiome therapeutics to impact immune biology.

Guest speakers scheduled to present at the event include:

  • Will Dere, M.D., University of Utah Health Sciences Center; Seres board member
  • Stephen Hanauer, M.D., Northwestern University Feinberg School of Medicine
  • Alan Moss, M.D., Beth Israel Deaconess Medical Center
  • Jennifer Wargo, M.D., M.M.Sc., MD Anderson Cancer Center

A live audio webcast of the presentation and accompanying slides will be available under the “Investors and Media” section of Seres’ website. A replay of the presentation will become available approximately one hour after the event and will be archived for 21 days.

About Seres Therapeutics

Seres Therapeutics, Inc. is a leading microbiome therapeutics platform company developing a novel class of biological drugs that are designed to treat disease by restoring the function of a dysbiotic microbiome, where the state of bacterial diversity and function is imbalanced. Seres’ lead program, SER-109, has obtained Breakthrough Therapy and Orphan Drug designations from the U.S. Food and Drug Administration and is in Phase 3 development for multiply recurrent C. difficile infection. Seres’ clinical candidate SER-287 has successfully completed a Phase 1b study in patients with mild-to-moderate Ulcerative Colitis. Seres is also developing SER-262, the first ever synthetic microbiome therapeutic candidate, in a Phase 1b study in patients with primary C. difficile infection. For more information, please visit Follow us on Twitter @SeresTx.

Source: Seres Therapeutics, Inc.

IR or PR Contact:
Seres Therapeutics
Carlo Tanzi, Ph.D., 617-203-3467
Vice President, Investor Relations and Corporate Communications

Shareholder Tools